# BioNTechs Oncology Pivot Gets Real - Date: 2026-04-13 - Category: Biotech & Life Sciences A 49% response rate in recurrent endometrial cancer where chemo delivers 15% is the strongest evidence yet that BioNTechs post-pandemic oncology pivot is beginning to deliver. ---